Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FURIN | P09958 | 3/20 | 0.52 |
| ▸ | PCSK6 | P29122 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.39 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
| ▸ | HPN | P05981 | 1/20 | 0.37 |
| ▸ | HGFAC | Q04756 | 1/20 | 0.37 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29577402 | 1.00 | FURIN (0.52) | FURINPCSK6SMN1; SMN2SIRT6SIRT1 | |
| SCHEMBL9495059 | 0.92 | FURIN (0.45) | FURINPCSK6SIRT6SIRT1ALDH1A1 | |
| SCHEMBL9495080 | 0.92 | FURIN (0.45) | FURINPCSK6SIRT6SIRT1ALDH1A1 | |
| SCHEMBL29514837 | 0.87 | SMN1; SMN2 (0.46) | FURINPCSK6SMN1; SMN2SIRT6SIRT1 | |
| SCHEMBL11094153 | 0.84 | SMN1; SMN2 (0.42) | FURINPCSK6SMN1; SMN2 | |
| SCHEMBL26429404 | 0.83 | FURIN (0.44) | FURINPCSK6 | |
| SCHEMBL25519403 | 0.81 | CTSK (0.43) | FURINPCSK6SMN1; SMN2SIRT6SIRT1 | |
| SCHEMBL8387889 | 0.80 | CTSK (0.57) | ALDH1A1CTSKCTSL | |
| SCHEMBL8695376 | 0.80 | CTSK (0.57) | ALDH1A1CTSKCTSL | |
| SCHEMBL8972183 | 0.80 | CTSK (0.57) | ALDH1A1CTSKCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3160590-B1 | NUTRIENTS SOLUTIONS FOR ENHANCEMENT OF COGNITIVE FUNCTION | MITOCHONDRIAL SUBSTRATE INVENTION LTD (GB) | 2018-04-25 | — | — | EP | disclosed |
| US-20180028473-A1 | NUTRIENTS SOLUTIONS | Mitochondrial Substrate Invention Ltd. (GB) | 2018-02-01 | — | — | US | disclosed |
| EP-3160590-A1 | NUTRIENTS SOLUTIONS FOR ENHANCEMENT OF COGNITIVE FUNCTION | Mitochondrial Substrate Invention Limited (GB) | 2017-05-03 | — | — | EP | disclosed |
| WO-2016001643-A1 | NUTRIENTS SOLUTIONS FOR ENHANCEMENT OF COGNITIVE FUNCTION | Mitochondrial Substrate Invention Limited (GB) | 2016-01-07 | — | — | WO | disclosed |
| US-20150374745-A1 | NUTRIENTS SOLUTIONS FOR ENHANCEMENT OF COGNITIVE FUNCTION | Mitochondrial Substrate Invention Limited (GB) | 2015-12-31 | — | — | US | disclosed |
| US-20100216875-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-08-26 | — | — | US | disclosed |
| EP-2099476-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | HOOK, Gregory (US) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008077109-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | HOOK GREGORY (US) | 2008-06-26 | — | — | WO | disclosed |
| WO-2004070009-A2 | TARGETED MULTIVALENT MACROMOLECULES | TARGESOME INC. (US) | 2004-08-19 | — | — | WO | disclosed |
| EP-1401818-A2 | TARGETED MULTIVALENT MACROMOLECULES | Targesome, Inc. (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20030133972-A1 | Targeted multivalent macromolecules | TARGESOME, INC. | 2003-07-17 | — | — | US | disclosed |
| US-20030129223-A1 | Therapeutic agents, comprising a linking carrier, a therapeutic entity associated with the linking carrier, and atleast one targeting entity | TARGESOME, INC. | 2003-07-10 | — | — | US | disclosed |
| WO-2002096367-A2 | TARGETED MULTIVALENT MACROMOLECULES | TARGESOME, INC. (US) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150374745-A1 | NUTRIENTS SOLUTIONS FOR ENHANCEMENT OF COGNITIVE FUNCTION | CHAT, SLC18A3, SLC25A20 | FURIN 3110/4885PCSK6 1565/4885SMN1; SMN2 412/4885 |
| US-20030133972-A1 | Targeted multivalent macromolecules | CLTB, ILK, CD44 | FURIN 1565/4885PCSK6 1363/4885SMN1; SMN2 2078/4885 |
| US-20030129223-A1 | Therapeutic agents, comprising a linking carrier, a therapeutic entity associated with the linking carrier, and atleast one targeting entity | CD47, TSG101, ILK | FURIN 1511/4885PCSK6 1151/4885SMN1; SMN2 1098/4885 |
| US-20100216875-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | CTSB, BACE2, BACE1 | FURIN 138/4885PCSK6 158/4885SMN1; SMN2 3353/4885 |
| US-20180028473-A1 | NUTRIENTS SOLUTIONS | SLC10A2, SLC5A6, SLC6A6 | FURIN 2292/4885PCSK6 1284/4885SMN1; SMN2 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.